The first clinically approved BRAF inhibitors, vemurafenib and dabrafenib, are effective in melanoma driven by V600E BRAF, but they are less effective in other contexts and can accelerate the progression of cutaneous squamous cell carcinomas (55). Here, BRAF is linked to cutaneous squamous cell carcinoma.